A New Era in the Prevention and Management of CMV Infection

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management of CMV

These are archives of live webinars held between July 23, 2021 to July 28, 2021

If you participated in any of the live webinars, you are not eligible to claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all three or in order.

These activities are valid from September 1, 2021 to September 1, 2023

This series is supported by an educational grant from
Merck

 Audience: This activity is intended for healthcare professionals practicing in managed care environments.

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Cytomegalovirus (CMV) infection remains a frequent complication in hematopoietic stem cell transplantation (HSCT) and solid organ transplantation (SOT) recipients. In addition to causing a variety of end-organ diseases, CMV infection is also associated with rejection after SOT and with graft versus host disease (GVHD) after HSCT. Antiviral prophylaxis is effective against direct and indirect effects of CMV infection. Preemptive therapy, more commonly used after HSCT, is based on surveillance, and targets therapy to patients at highest risk. Novel antiviral therapies with different mechanisms of action have recently become available giving healthcare professionals new options in the management of this infection. This program will take a look at those advances and provide up to date strategies for the management of CMV infection.

This webinar series on the evolving role of novel therapies in CMV infection management will take a close look at recent guideline updates, clinical data, and strategies for the prevention and management of CMV.

Recent Advances in the Prevention and Management of Cytomegalovirus (CMV) Infection in Transplant Recipients: Managed Care Considerations for Improved Outcomes

1. Summarize the economic burden of cytomegalovirus (CMV) disease and challenges associated with its management
2. Analyze unmet needs associated with historical strategies to prevent CMV disease in transplant recipients
3. Examine recent guideline updates and expert recommendations around the management of CMV in transplant patients
4. Discuss the managed care professional’s role in the treatment and prevention of infection from CMV

A New Era in the Prevention and Management of Cytomegalovirus (CMV) Infection in Transplant Recipients: Assessing the Evidence in Real-world Applications

1. Describe patient populations and procedures associated with the greatest risk for negative outcomes due to CMV infection or reactivation
2. Incorporate recent evidence into practice regarding the use of prophylactic and preemptive measures to prevent cytomegalovirus (CMV) disease in transplant recipients
3. Differentiate conventional versus newer antiviral therapies in terms of safety and efficacy, ability to reduce CMV reactivation, and improvement of survival in transplant recipients
4. Evaluate the optimal duration of prophylactic or preemptive treatment in patients at risk for CMV reactivation
5. Review recent guideline statements and expert recommendations for CMV infection management, prevention, and follow-up care